EXCELLABIO LLC
🇺🇸United States
Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients
Phase 2
Terminated
- Conditions
- Gastric CancerOvarian CancerBreast Cancer Female
- Interventions
- Biological: NivolumabBiological: Ipilimumab
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- ExcellaBio LLC
- Target Recruit Count
- 5
- Registration Number
- NCT03342417
- Locations
- 🇺🇸
Hoffman Oncology, Bronx, New York, United States
© Copyright 2025. All Rights Reserved by MedPath